Search company, investor...
Solo-Dex company logo



Grant | Alive

About Solo-Dex

Solo-Dex is a medical device company, founded by anesthesiologists for anesthesiologists, that aims to promote the use of nerve catheters for pain management by using Continuous Peripheral Nerve Blocks (CPNB) for orthopedic surgery.

Headquarters Location

2820 Wilderness Place

Boulder, Colorado, 80301,

United States

Missing: Solo-Dex's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Solo-Dex's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Solo-Dex

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Solo-Dex is included in 2 Expert Collections, including Medical Devices.


Medical Devices

11,721 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,901 items

Solo-Dex Patents

Solo-Dex has filed 7 patents.

The 3 most popular patent topics include:

  • Anesthesia
  • Dosage forms
  • General anesthetics
patents chart

Application Date

Grant Date


Related Topics




Medical equipment, Anesthesia, Medical ultrasonography, Regional anesthesia, Catheters


Application Date


Grant Date



Related Topics

Medical equipment, Anesthesia, Medical ultrasonography, Regional anesthesia, Catheters



Latest Solo-Dex News

InfuSystem Announces Agreement with Solo-Dex for Continuous Peripheral Nerve Block Catheters

Feb 22, 2022

February 22, 2022 06:30 AM Eastern Standard Time ROCHESTER HILLS, Mich.--( BUSINESS WIRE )--InfuSystem Holdings, Inc. (NYSE American: INFU), (“InfuSystem” or the “Company), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today announced a national distribution agreement with Solo-Dex, Inc. for its proprietary continuous nerve block catheters. With Solo-Dex catheter over the needle technology, all anesthesiologists can place facile continuous peripheral block catheter in two to three minutes for common procedures such as shoulder repair, hip and knee replacement as well as general surgical procedures. Once placed, Solo-Dex products are designed to remain in place introducing the type, quantity and volume of acute pain management medication continuously for days. “InfuSystem is pleased to join with Solo-Dex in bringing innovation to the acute pain management market. Solo-Dex will bring technology to our customers that makes it easier for the anesthesiologist to place nerve block catheters safely and effectively. As a result, we believe more patients will have the opportunity to receive our services and recover quickly without requiring the use of oral opioid pain management,” said Richard DiIorio, Chief Executive Officer of InfuSystem. “Solo-Dex Facile, coupled with InfuSystem’s InfuBLOCK Pain Management Therapy program and follow-up services, are now collaborating to bring cost effective, easy-to-use continuous regional acute pain management to a market which is estimated to be 10 times larger than the current nerve catheter market,” remarked Steve Eror, CEO of Solo-Dex. “The stage is set for the emergence of a new standard of care.” Continuous regional anesthesia coupled with mild sedation may eliminate the need for a patient to receive general anesthesia which requires the manipulation of the airway, may disrupt the patient’s cognition and extends recovery. For the surgical team, manipulation of the airway may increase the risk of COVID-19 exposure for the surgical team. Safe and effective acute pain management can be delivered via continuous peripheral nerve block, days before, during and after surgery. The patient tends to recover more quickly and may be released for home recovery with a block that eliminates the need for oral opioid painkillers. On February 2, 2022, Stanford University and The Lancet published its expectation that in North America over one million more opioid deaths by 2029. About Solo-Dex, Inc. Solo-Dex is a private company founded by leading anesthesiologists to reduce the cost and risk associated with general anesthesia by improving surgical patient recovery times, reducing medical personnel exposure to COVID-19, reducing or eliminating the misuse of opioid-related pain management, and by safely and effectively managing pain before, during and after a procedure. Solo-Dex offers a family of proprietary catheter over the needle anesthesia products, and related devices to assist anesthesiologists manage their patient’s acute pain. Additional information about Solo-Dex is available at . About InfuSystem Holdings, Inc. InfuSystem Holdings, Inc. (NYSE American: INFU), is a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-platform model. The lead platform is Integrated Therapy Services (“ITS”), providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The ITS segment is comprised of Oncology, Pain Management, Wound Therapy and Lymphedema businesses. The second platform, Durable Medical Equipment Services (“DME Services”), supports the ITS platform and leverages strong service orientation to win incremental business from its direct payer clients. The DME Services segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada. Forward-Looking Statements Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements relating to future actions, our share repurchase program and capital allocation strategy, business plans, objectives and prospects, future operating or financial performance and guidance. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “strategy,” “future,” “likely,” variations of such words, and other similar expressions, as they relate to the Company, are intended to identify forward-looking statements. Forward-looking statements are subject to factors, risks and uncertainties that could cause actual results to differ materially, including, but not limited to, the uncertain impact of the COVID-19 pandemic, our dependence on estimates of collectible revenue, potential litigation, changes in third-party reimbursement processes, changes in law, contributions from acquired businesses or new business lines, products or services and other risk factors disclosed in the Company’s most recent annual report on Form 10-K and, to the extent applicable, quarterly reports on Form 10-Q. All forward-looking statements made in this press release speak only as of the date hereof. We do not undertake any obligation to update any forward-looking statements to reflect future events or circumstances, except as required by law. Additional information about InfuSystem Holdings, Inc. is available at . Contacts Lytham Partners, LLC

Solo-Dex Frequently Asked Questions (FAQ)

  • Where is Solo-Dex's headquarters?

    Solo-Dex's headquarters is located at 2820 Wilderness Place, Boulder.

  • What is Solo-Dex's latest funding round?

    Solo-Dex's latest funding round is Grant.

  • Who are the investors of Solo-Dex?

    Investors of Solo-Dex include Colorado Office of Economic Development and International Trade.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.